Stereotactic body radiotherapy for metastatic sarcoma to the lung: adding to the arsenal of local therapy
Tóm tắt
Conventional treatment of pulmonary metastatic sarcoma primarily involves surgery, with systemic therapy added in select patients. However, broader applications of radiation therapy techniques have prompted investigation into the use of stereotactic body radiotherapy (SBRT) for treatment of metastatic sarcoma, an attractive non-invasive intervention with potential for lower rates of adverse events than surgery. Current data are limited to retrospective analyses. This study analyzed 2-year local control and overall survival and adverse events in patients prospectively treated with SBRT to pulmonary sarcoma metastases. Patients prospectively treated with SBRT to the lung for biopsy-proven metastatic sarcoma at a single institution from 2010 to 2022 were included. SBRT dose/fractionation treatment regimens ranged from 34 to 54 Gy in 1–10 fractions using photons. Local recurrence, local progression-free survival (LPFS) and overall survival (OS) were calculated from the end of SBRT. Univariable analysis (UVA) was performed using the log-rank test. Multivariable analysis (MVA) was performed using the Cox proportional hazards model. Adverse events due to SBRT were graded based on the Common Terminology Criteria for Adverse Events, version 4.0. Eighteen patients with metastatic sarcoma were treated to 26 pulmonary metastases. The median local progression-free survival was not met. The median overall survival was not met. The local control rate at 2 years was 96%. 2-year LPFS was 95.5% and OS was 74%. Three patients (16.7%) developed grade 1 adverse events from SBRT. There were no adverse events attributed to radiation that were grade 2 or higher. We report prospective data demonstrating that SBRT for sarcoma pulmonary metastases affords a high rate of local control and low toxicity, consistent with prior sarcoma SBRT retrospective data. This study adds to the wealth of information on SBRT in a radioresistant tumor. Though largely limited to retrospective reviews, current data indicate high rates of local control with favorable toxicity profiles. Therefore, SBRT for pulmonary sarcoma metastases may be considered for properly selected patients.
Tài liệu tham khảo
Gadd MA, Casper ES, Woodruff JM, McCormack PM, Brennan MF. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg. 1993;218(6):705–12.
Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma. Ann Surg. 1999;229(5):602.
Sarcomas, Soft Tissue—Statistics. Cancer.Net. Published June 25, 2012. Accessed September 27, 2022. https://www.cancer.net/cancer-types/sarcomas-soft-tissue/statistics
Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20(4):494–503. https://doi.org/10.1016/S1470-2045(18)30896-9.
Singh D, Chen Y, Hare MZ, et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis. 2014;6(4):369–74. https://doi.org/10.3978/j.issn.2072-1439.2013.12.03.
Okunieff P, Petersen AL, Philip A, et al. Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol Stockh Swed. 2006;45(7):808–17. https://doi.org/10.1080/02841860600908954.
Haas RL, Floot BGJ, Scholten AN, et al. Cellular radiosensitivity of soft tissue sarcoma. Radiat Res. 2021;196(1):23–30. https://doi.org/10.1667/RADE-20-00226.1.
Elledge CR, Krasin MJ, Ladra MM, et al. A multi-institutional phase 2 trial of stereotactic body radiotherapy in the treatment of bone metastases in pediatric and young adult patients with sarcoma. Cancer. 2021;127(5):739–47. https://doi.org/10.1002/cncr.33306.
Rhomberg W. The radiation response of sarcomas by histologic subtypes: a review with special emphasis given to results achieved with razoxane. Sarcoma. 2006;2006:87367. https://doi.org/10.1155/SRCM/2006/87367.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.
Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–7. https://doi.org/10.1016/S1470-2045(15)70168-3.
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(25):2830–8. https://doi.org/10.1200/JCO.20.00818.
Nestle U, Adebahr S, Kaier K, et al. Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. Radiother Oncol. 2020;148:82–8. https://doi.org/10.1016/j.radonc.2020.03.018.
van Leeuwen CM, Oei AL, Crezee J, et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol. 2018;13(1):96. https://doi.org/10.1186/s13014-018-1040-z.
Yang G, Yuan Z, Ahmed K, et al. Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization. Transl Oncol. 2021;14(10):101165. https://doi.org/10.1016/j.tranon.2021.101165.
Baumann BC, Bernstein KDA, DeLaney TF, et al. Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity. J Surg Oncol. 2020;122(5):877–83. https://doi.org/10.1002/jso.26078.
Dhakal S, Corbin KS, Milano MT, et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol. 2012;82(2):940–5. https://doi.org/10.1016/j.ijrobp.2010.11.052.
Frakulli R, Salvi F, Balestrini D, et al. Stereotactic radiotherapy in the treatment of lung metastases from bone and soft-tissue sarcomas. Anticancer Res. 2015;35(10):5581–6.
Lindsay AD, Haupt EE, Chan CM, et al. Treatment of sarcoma lung metastases with stereotactic body radiotherapy. Sarcoma. 2018;2018:1–6. https://doi.org/10.1155/2018/9132359.
Navarria P, Ascolese AM, Cozzi L, et al. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. Eur J Cancer. 2015;51(5):668–74. https://doi.org/10.1016/j.ejca.2015.01.061.
Navarria P, Baldaccini D, Clerici E, et al. Stereotactic body radiation therapy for lung metastases from sarcoma in oligometastatic patients: a phase 2 study. Int J Radiat Oncol Biol Phys. 2022;114(4):762–70. https://doi.org/10.1016/j.ijrobp.2022.08.028.
Soyfer V, Corn BW, Shtraus N, et al. Single-institution experience of SBRT for lung metastases in sarcoma patients. Am J Clin Oncol. 2017;40(1):83–5. https://doi.org/10.1097/COC.0000000000000103.
Tetta C, Londero F, Micali LR, et al. Stereotactic body radiotherapy versus metastasectomy in patients with pulmonary metastases from soft tissue sarcoma. Clin Oncol. 2020;32(5):303–15. https://doi.org/10.1016/j.clon.2020.01.005.
Gutkin PM, von Eyben R, Chin A, et al. Local control outcomes using stereotactic body radiation therapy or surgical resection for metastatic sarcoma. Int J Radiat Oncol. 2022. https://doi.org/10.1016/j.ijrobp.2022.05.017.